徐莉莉 - 中国药科大学

个人简介

徐莉莉，药物化学博士，副研究员，硕士生导师。2017年硕博连读毕业于中国药科大学制药工程学专业，同年进入药物分析系从事师资博士后研究工作，2020年7月博士后出站留校担任讲师，2021年7月获聘副研究员职称。

研究领域

运用药物分析学、蛋白质组学、化学生物学、药物化学、计算机辅助药物设计等多学科交叉手段，开展基于非可控性炎症疾病的原创药物研发、分子探针及蛋白质组学在靶标发现与确证中的应用、基于探针分子的新分析方法研究等。

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Li, C. C.; Zhao, N.;An, L. Y.;Dai, Z.; Chen, X. Y.; Yang, F.; You, Q. D.;Di, B.*;Hu, C.*; Xu, L. L.*, Apoptosis-inducing activity of synthetic hydrocarbon-stapled peptides in H358 cancer cells expressing KRASG12C, Acta Pharmaceutica Sinica B, 2021, 11(9), 2670e2684. (IF = 11.413) Jia, J.; Wen, H.; Zhao, S.; Wang, L.; Qiao, H.; Shen, H.; Yu, Z.; Di, B.*; Xu, L. L.*; Hu, C.*, Displacement Induced Off-On Fluorescent Biosensor Targeting IDO1 Activity in Live Cells, Analytical Chemistry, 2019,91 (23), 14943-14950. (IF = 6.986) Dai, Z.; Chen, X. Y.; An, L. Y.; Li, C. C.; Zhao, N.; Yang, F.; You, S. T.; Hou, C. Z.; Li, K.; Jiang, C.*; You, Q. D.*; Di, B.*; Xu, L. L.*, Development of Novel Tetrahydroquinoline Inhibitors of NLRP3 Inflammasome for Potential Treatment of DSS-Induced Mouse, Journal of Medicinal Chemistry, 2021,64, 871-889. (IF =7.446) Cheng, S.; Shen, H.; Zhao, S.; Zhang, Y.; Xu, H.; Wang, L.; Di, B.*; Xu, L. L.*; Hu, C.*, Orally administered mesoporous silica capped with the cucurbit[8]uril complex to combat colitis and improve intestinal homeostasis by targeting the gut microbiota, Nanoscale, 2020,12(28), 15348-15363. (IF =7.79) Zhao, N.; Li, C. C.; Di, B.*; Xu, L. L.*, Recent advances in the NEK7-licensed NLRP3 inflammasome activation: Mechanisms, role in diseases and related inhibitors, Journal of Autoimmunity, 2020, 113, 102515. (IF = 7.094) Xu, L. L.; Wu, Y. F.; Yan, F.; Li, C. C.; Dai, Z.; You, Q. D.*; Jiang, Z. Y.*; Di, B.*, 5-(3,4-Difluorophenyl)-3-(6-methylpyridin-3-yl)-1,2,4-oxadiazole (DDO-7263), a novel Nrf2 activator targeting brain tissue, protects against MPTP induced subacute Parkinson's disease in mice by inhibiting the NLRP3 inflammasome and protects PC12 cells against oxidative stress, Free Radical Biology and Medicine, 2019,134, 288-303. (IF = 7.376) Zhao, N.; Di, B.*; Xu, L. L.*, The NLRP3 inflammasome and COVID-19: Activation, pathogenesis and therapeutic strategies. Cytokine and Growth Factor Reviews,2021,61, 2–15. (IF = 7.638) Xu, L. L.; Li, C. C.; An, L. Y.; Dai, Z.; Chen, X. Y.; You, Q. D.*; Hu, C.*; Di, B.*, Selective apoptosis-inducing activity of synthetic hydrocarbon-stapled SOS1 helix with D-amino acids in H358 cancer cells expressing KRASG12C, European Journal of Medicinal Chemistry, 2020,185, 111844. (IF =6.514) Xu, L. L.; Wu, Y. F.; Wang, L.; Li, C. C.; Li, L.; Di, B.*; You, Q. D.*; Jiang, Z. Y.*, Structure-activity and structure-property relationships of novel Nrf2 activators with a 1,2,4-oxadiazole core and their therapeutic effects on acetaminophen (APAP)-induced acute liver injury, European Journal of Medicinal Chemistry, 2018,157, 1376-1394. (IF =6.514)